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CalpainThe synaptosomal plasma membrane Ca2+-ATPase (PMCA) plays an essential role in regulating intracellular
Ca2+ concentration in brain. We have recently found that PMCA is the only Ca2+ pump in brain which is
inhibited by amyloid-β peptide (Aβ), a neurotoxic peptide implicated in the pathology of Alzheimer's disease
(AD) [1], but the mechanism of inhibition is lacking. In the present study we have characterized the inhibition
of PMCA by Aβ. Results from kinetic assays indicate that Aβ aggregates are more potent inhibitors of PMCA
activity than monomers. The inhibitory effect of Aβ could be blocked by pretreating the puriﬁed protein
with Ca2+-calmodulin, the main endogenous activator of PMCA, and the activity of truncated PMCA lacking
the calmodulin binding domain was not affected by Aβ. Dot-overlay experiments indicated a physical asso-
ciation of Aβ with PMCA and also with calmodulin. Thus, calmodulin could protect PMCA from inhibition
by Aβ by burying exposed sites on PMCA, making them inaccessible to Aβ, and also by direct binding to
the peptide. These results suggest a protective role of calmodulin against neuronal Ca2+ dysregulation by
PMCA inhibition induced by Aβ.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
The plasmamembrane Ca2+-ATPases (PMCAs) are P-type ATPases
with very high afﬁnity for Ca2+, transporting Ca2+out of the cell
coupled to the hydrolysis of ATP. PMCA proteins are encoded by
four genes (ATP2B1–4), with more than 20 variants generated by al-
ternative splicing [2]. These pumps are predicted to contain 10 trans-
membrane α-helices with two major cytosolic loops involved in
PMCA function and regulation. They also contain a C-terminal tail,
missing in intracellular Ca2+ pumps, that plays a key role in regula-
tion of PMCA activity [3–5]. Thus, this tail is involved in protein auto-
inhibition, binds to calmodulin, acidic phospholipids and ethanol, and
provides sites for modiﬁcation by phosphorylation. A strong interac-
tion of the C-terminal tail with the transduction and catalytic do-
mains of PMCA results in an autoinhibitory conformation by burying
the catalytic core of the ATPase [6–8]. Calmodulin, the ubiquitous in-
tracellular Ca2+ sensor, binds to a calmodulin-binding domain locat-
ed in the C-terminal tail, and removes PMCA autoinhibition by
changing the pump conformation and stimulating activity. The high
afﬁnity of PMCA for calmodulin has been widely used to purifyer's disease; PBS, Phosphate
ma membrane Ca2+-ATPase;
rights reserved.PMCA from a variety of tissues, including brain [9]. The puriﬁed pro-
tein is obtained in a delipidated, inactive form but can be partially
or fully activated by reconstitution in phosphatidylcholine (PC) or
phosphatidylserine (PS), respectively, as previously described [9]. It
has been shown that calmodulin can fully activate the PC-
reconstituted PMCA in the presence of Ca2+, but that it does not affect
the activity of the PS-reconstituted PMCA. Besides, the removal of the
autoinhibitory domain by proteolysis or mutagenesis drives the pro-
tein to maximal activity [10–12].
PMCAs are important in Ca2+ homeostasis and signal transduction
in the nervous system (reviewed in [13]) where Ca2+ dyshomeostasis
is a critical feature in many neurodegenerative diseases. In the Ca2+
hypothesis of Alzheimer's disease (AD), disruption of Ca2+ signaling
is a key factor in neuronal dysfunction [14,15] and we have recently
presented evidence for an impairment of PMCA activity in AD linked
to an inhibitory effect of the neurotoxic amyloid-β peptide (Aβ) [1].
However, a clear understanding of the mechanism of inhibition is
lacking. On the other hand it has been shown that calmodulin content
in AD affected brains was signiﬁcantly reduced (66% of that found in
brains of patients who died of a dementia process other than AD and
in normal control brains [16]). Taking into account these consider-
ations, in this work, we have characterized the functional effect of
Aβ on PMCA and its relationship with calmodulin. We analyzed
the effect of Aβ length and aggregation on PMCA inhibition, and
described a protective role of calmodulin on Aβ-mediated PMCA inhi-
bition. Thus, calmodulin may be an important mediator of Ca2+ dys-
regulation in AD due to its interaction with both Aβ and with PMCA.
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2.1. Materials
Bovine testes calmodulin, phosphatidylcholine (PC) type XI-E from
egg yolk, calmodulin-agarose, chymotrypsin and anti-βtubulin anti-
body were obtained from Sigma. Calpain (μ-calpain) and biotinylated-
calmodulin were from Calbiochem. Peptides Aβ25-35, and Aβ1-40
were obtained from AnaSpec and Aβ1-42 and scrambled Aβ42-1 were
synthesized by StabVida.
2.2. Preparation of fresh and aggregated Aβ peptides
Aβ25-35 was dissolved in distilled water to make a 2 mg/ml stock
solution. Aβ1-40, Aβ1-42 and Aβ42-1 were dissolved in 70 μl of 1%
NH4OH to give a clear solution, and then diluted with 100 mM
Hepes/KOH (pH 7.4) to prepare a 4 mg/ml stock solution. Peptides
were used immediately or were incubated at 37 °C to prepare aggre-
gates. An optimal time of 2 h incubation was typically used (and re-
ferred as “aged” peptide).
2.3. Preparation of puriﬁed plasma membrane Ca2+-ATPase from
pig cerebrum
The pig brain plasma membrane Ca2+-ATPase (PMCA) was puri-
ﬁed as described by [9]. Brieﬂy, fresh pig brain from adult pig
(5 months-old), was homogenized in 10 volumes of 10 mM Hepes/
KOH (pH 7.4), 0.32 M sucrose, 0.5 mMMgSO4, 0.1 mM phenylmethyl-
sulfonylﬂuoride and 2 mM 2-mercaptoethanol. After two centrifuga-
tions at low and high speed, respectively, synaptosomes were
obtained by discontinuous 20–40% (w/v) sucrose gradient centrifuga-
tion and lysed in a hypotonic medium. Synaptosomal plasma mem-
brane vesicles were obtained by centrifugation of the pellet and
were solubilized in a medium containing 20 mM Hepes/KOH (pH
7.4), 130 mM KCl, 0.5 mM MgCl2, 50 μM CaCl2, 15% glycerol, 2 mM
2-mercaptoethanol, and 0.6% (w/v) Triton X-100. The solubilized
fraction was applied to a calmodulin-agarose column and PMCA was
eluted with a buffer containing 15% glycerol, 0.06% (w/v) Triton X-
100 and 2 mM EDTA instead of calcium. Samples were stored at
−80 °C until use.
The protein content was evaluated by the Bradford method [17],
using bovine serum albumin as a protein standard.
2.4. Ca2+-ATPase activity
The activity of puriﬁed PMCA from pig brain was measured with a
coupled enzyme assay, as described in [9], using 2.5 μg of delipidated
protein reconstituted with PC (13.3 μg). The effects of Aβ and/or pre-
treatment with calmodulin were assayed by incubating PMCA for 3 or
10 min at 25 °C with Aβ and/or calmodulin, in a ﬁnal volume of 25 μl.
The mixture was then diluted directly into the assay medium,
containing 50 mM Hepes/KOH (pH 7.4), 100 mM KCl, 2 mM MgCl2,
5 mM Na3N, 3.16 μM free Ca2+ (pCa 5.5), 0.22 mM NADH, 0.42 mM
phosphoenolpyruvate, 10 IU pyruvate kinase, and 28 IU lactate dehy-
drogenase, in 1 ml ﬁnal volume. The activity was measured after trig-
gering the reaction with 1 mM ATP and, when indicated, after
addition of 200 nM calmodulin to the reaction medium. Thus, results
will be referred to calmodulin and Aβ ﬁnal concentrations in 1 ml ac-
tivity assay.
The enzymatic activity of overexpressed PMCA from COS-7 cells
was measured in 10 μg of membrane vesicles and the effects of Aβ
and/or pretreatment with calmodulin were assayed by incubating
membranes as above, with 30 μM peptide and/or 400 nM calmodulin,
respectively. The mixture was added to 1 ml of standard assay medi-
um which also contained 0.01% saponin (to disrupt both the plasma
and intracellular membranes, allowing the access of substrates to allprotein molecules in membrane vesicles). The reaction was started
with 1 mM ATP, and further activation by calmodulin was checked
by adding 400 nM calmodulin to the medium.
2.5. Dot-blot overlay binding assay
Aβ peptides or puriﬁed PMCAwere loaded on nitrocellulose mem-
brane by using a Bio-Dot® Microﬁltration Apparatus (BioRad). The
membrane was then blocked with PBS-1% Tween 20 containing 2%
(w/v) low-fat milk for 1 h at RT and incubated with 0.3 μg/μl biotiny-
lated PMCA in PBS-0.05% Tween 20 (PBS-T) or with 0.5 μg/μl biotiny-
lated calmodulin (Calbiochem) in PBS-T in the absence or presence of
0.5 mM CaCl2 for 2 h at 37 °C. After several washing steps with PBS-T
to remove unbound biotinylated protein, the membrane was incubat-
ed with ExtrAvidin-Peroxidase (1:2000, Sigma) in PBS-T for 1 h at RT.
After one wash with PBS-T and two washes with PBS, the membrane
was developed with ECL substrate and spots were visualized with
a Chemidoc™ XRS+Imaging System (BioRad), and quantiﬁed with
Image Lab™ software 3.0 (BioRad).
2.6. PMCA biotinylation
A 38:1 molar ratio of biotin to PMCA (equivalent to 0.33 mol of bi-
otin per lysine) was used. Brieﬂy, a 0.1 mg/ml stock solution of Sulfo-
NHS biotin (ProteoChem) was prepared in 50 mM sodium bicarbon-
ate (pH 8.0) buffer immediately prior to use. Then 2.7 μg of biotin
was mixed with 22.5 μg of PMCA and incubated for 2 h on ice. Free bi-
otin was removed through a 50 kDa Cut-off microcone centrifuge ﬁl-
ter (Millipore).
2.7. Negative staining and transmission electron microscopy
Aβ1-40 and 1–42, and the corresponding Aβ 40–1 and 42–1
scrambles were diluted to 188 μM in 100 mM Hepes/KOH (pH 7.4).
Aβ ﬁbrillogenesis was induced by incubation at 37 °C for 30 min, 2 h
and 3 days. For negative staining, carbon-coated grids were ﬂoated
on the peptide solutions for 5 min, dried and stained with 2% uranyl
acetate for 1 min. After washing in milliQ water, grids were air
dried and visualized by transmission electron microscopy (JEM1010
Jeol).
2.8. Digestion with proteases
Puriﬁed pig brain PMCA (2.5 μg) was incubated with 0.025 μg chy-
motrypsin or 0.5 μg calpain in buffer containing 100 mM KCl, 3.16 μM
free Ca2+, 25 mM Hepes/KOH (pH 7.4), in 25 μl ﬁnal volume, on ice.
Proteolysis was stopped after the indicated time by addition of the
protease inhibitor phenylmethyldulfonyl ﬂuoride (PMSF) to a ﬁnal
concentration of 2 mM. Samples were then incubated in the presence
or absence of 30 μM 2 h-aged Aβ1-42 for 3 min at 25 °C for activity
assays.
Alternatively, PMCA digestion was stopped by precipitation with
8% trichloroacetic acid. Samples were centrifuged at 15,000 ×g
for 15 min at 4 °C and pellets were washed with 200 μl of 10 mM
Hepes/KOH (pH 7.4) and solubilised in 20 μl Laemmli's buffer [18].
The samples were then subjected to electrophoretic analysis on 6.5%
gels followed by staining with Coomasie Blue.
2.9. Construction of truncated hPMCA4b and expression in COS-7 cells
hPMCA4b cDNA cloned in pMM2 was kindly provided by Dr. E. E.
Strehler (Mayo Clinic, Rochester, MN, USA). Using this vector as tem-
plate, a site-directed mutagenesis PCR was carried out using 5′-
CATGCTGAGATGGAGTGACGCCGAGGCCAGATCC-3′ and 5′- GGATCTG-
GCCTCGGCGTCACTCCATCTCAGCATG-3′. The reverse primer contains
a stop codon (underlined) to truncate the protein immediately after
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at the C-terminus, including the 28-residue calmodulin-binding
inhibitory domain. The construct was checked by sequencing.
The wild-type and mutant cDNAs cloned in pMM2 were used forFig. 1. Ageing of Aβ peptides and their effects on PMCA activity. (A) Effect of Aβ ageing on
cubated for 2 min at 37 °C in a volume of 25 μl, with 30 μM of Aβ1-42 (●), Aβ1-40 (△), Aβ2
indicated times. Then incubates were diluted to 1 ml with the assay medium, giving a ﬁnal Aβ
Methods section. (B) Effect of Aβ concentration on PMCA activity. 2.5 μg of PMCA reconstitut
Aβ1-42 for 2 min. The sample was then transferred to 1 ml of assay medium, giving the in
Methods section. (C) Aβ-PMCA binding by Dot-blot overlay assay. Aβ1-42 (0.5 μg) freshly p
ative control, were spotted on Dot-blot nitrocellulose membrane and incubated with biotin
spot was calculated and represented as mean±SD from four different experiments (*, p≤0.
ysis of Aβ peptides and the scrambled sequences before and during ageing at 37 °C. Differe
cation of ×100 000. Scale bar: 0.2 μm.transfection in COS-7 cells using GenJuice transfection reagent
(Novagen). After incubation for 60 h at 37 °C and 5% CO2, membrane
vesicles were prepared from cells harvested from the plates, as de-
scribed by [19] and used for ATPase activity assays.Ca2+-ATPase activity. Pig cerebrum puriﬁed PMCA (2.5 μg) reconstituted in PC was in-
5-35 (○), or Aβ42-1 (□) peptides, freshly prepared or after incubation at 37 °C for the
concentration of 0.75 μM. Ca2+-ATPase activity was then measured as described in the
ed in PC was incubated in a volume of 25 μl, with increasing concentrations of 2 h-aged
dicated concentrations of Aβ. Ca2+-ATPase activity was measured as described in the
repared, 2 h-aged and 3 days-aged, and 2 h-aged scrambled Aβ42-1 (0.5 μg) as a neg-
ylated PMCA as described in the Methods Section. The relative signal intensity of each
05; **, p≤0.005, respect to 0 h ageing). (D) Negative staining electron microscopy anal-
nt aggregation stages are shown. All electron micrographs were recorded at a magniﬁ-
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Signiﬁcant differences were determined by an unpaired Student t-
test using the SigmaPlot v10 software (SPSS Inc, Chicago, IL). A
p≤0.05 value was considered statistically signiﬁcant.
3. Results
3.1. Inhibition of PMCA activity by Aβ peptide
In vitro aggregation of Aβ was induced by incubation at 37 °C and
was followed for 3 days. Fig. 1A shows that Aβ inhibits the Ca2+-
ATPase activity of puriﬁed PMCA reconstituted in PC, the degree of in-
hibition increasing with Aβ length and aggregation. Thus, the highest
PMCA inhibition was obtained with 0.75 μM Aβ1-42, a concentration
which inhibits ATPase activity by 50%, after 2 h ageing (Fig. 1B).
Scrambled peptide Aβ42-1 did not inhibit enzyme activity (Fig. 1A).
Similar results were found after reconstitution in PS (results not
shown). Dot blot assays (Fig. 1C), using Aβ1-42 or the scrambled pep-
tide with biotinylated PMCA were performed to prove Aβ-PMCA
binding. As shown, binding increased with peptide aggregation. The
inverted amino acid sequence of the 2 h-aged scrambled peptide
did not bind to PMCA (Fig. 1C). Negative-staining technique and elec-
tron microscopy were also performed to follow Aβ aggregation
(Fig. 1D). This revealed ﬁlament structures for all peptides after
3 days incubation, with Aβ1-42 aggregates forming an amorphous
structure after 2 h incubation. The scrambled peptides did not form
ﬁbrils.
Considering that calmodulin is the main activator of PMCA pump
in the presence of PC, as described in the Introduction, we analyzed
effects of calmodulin on PMCA reconstituted in PC. First (Fig. 2), it
was observed that inhibition of PMCA activity by 0.75 μM 2 h-aged
Aβ1-42 was incubation-time dependent. Second, 2-fold activation of
the protein was observed on addition of calmodulin to the assay me-
dium (at saturating concentrations of calmodulin) at all times of incu-
bation with peptide. Both curves ﬁt to an exponential decay curve,
showing that Aβ produced similar rates of inhibition in basal and
calmodulin-activated PMCA activities, with 50% inhibition in both
cases after 1.3 min incubation.
3.2. Protection of PMCA activity from Aβ inhibition
The effect of Aβ on PMCA was also analyzed after previous incuba-
tion of the protein with increasing concentrations of calmodulin. AsFig. 2. Kinetics of PMCA inhibition by Aβ. 2.5 μg of PMCA reconstituted in PC were in-
cubated with 30 μM 2 h-aged Aβ1-42 for the indicated times at 25 °C in a volume of
25 μl, and then added to the reaction mixture (1 ml total volume). Ca2+-ATPase activity
was measured as described in the Methods section, in the absence (○) or presence of
200 nM calmodulin (●). Data are mean±SD values from three experiments performed
in duplicate and with three different preparations.seen in Fig. 3A, 0.75 μM Aβ1-42 caused a 50% decrease of PMCA
basal activity but this level of inhibition was reduced by pre-
treatment of PMCA with calmodulin. Signiﬁcant protection of PMCA
activity against inhibition by Aβ was observed at calmodulin concen-
trations above 0.35 nM, corresponding to a 1/2140 molar ratio of cal-
modulin/Aβ. The effect of the peptide was completely blocked at
concentrations of calmodulin above 5 nM, equivalent to a molar
ratio of 1/150. These results show that PMCA has a much higher afﬁn-
ity for calmodulin than for Aβ. The protective effect of calmodulin was
only seen when calmodulin was activated by Ca2+; in the presence of
EGTA the apo-calmodulin was unable to protect PMCA from its inhi-
bition by Aβ (Fig. 3B).
Similar experiments were performed using ﬁxed concentrations of
calmodulin and increasing concentration of peptide (Fig. 4). Data
agree with those in Fig. 3A, showing that 5 nM calmodulin prevent
the inhibitory effect of 0.75 μM Aβ on PMCA activity. The results reveal
that Aβ afﬁnity for PMCA decreased when the protein was pre-treated
with calmodulin. Thus, the half maximal inhibitory concentration
(IC50) of Aβ increased from 0.62 μM in the absence of calmodulin, to
0.65, 0.68 and 0.9 μM, in the presence of 0.35, 1.25 and 5 nM calmodu-
lin, respectively. However, high concentrations of peptide suppress the
protective effect of calmodulin (insert in Fig. 4).
These results raise the possibility that the calmodulin-binding
domain of PMCA may be directly involved in its interaction with Aβ.
To analyze this hypothesis, PMCA was digested with chymotrypsin
or calpain, two proteases that cut the protein preferentially at the car-
boxyl terminus containing the calmodulin-binding domain [11,20,21].
Functional assays were then carried out with the resulting fragments
to explore the sensitivity of digested PMCA to Aβ. The time course ofFig. 3. Protective effect of calmodulin on PMCA inhibition by Aβ. (A) 2.5 μg of PMCA
reconstituted in PC were incubated for 10 min at 25 °C, in a volume of 25 μl, with in-
creasing concentrations of calmodulin in the presence of 3.16 μM free Ca2+. For the
samples containing Aβ (●), 30 μM 2 h-aged Aβ1-42 (1 μl) was then added and incubat-
ed for 3 min. Finally, incubates were diluted to 1 ml with assay medium, giving 0.75 μM
Aβ, and the indicated calmodulin ﬁnal concentrations. The Ca2+-ATPase activity was
measured as described in the Method section. (B) Assays were performed as in A,
using 14 and 200 nM calmodulin (giving ﬁnal concentrations of 0.35 and 5 nM in
1 ml ﬁnal volume) in the presence of 3.16 μM free Ca2+ (grey bars) or 2 mM EGTA
(white bars). Data represent mean±SD values from three experiments performed in
duplicate and with three different preparations (*, p≤0.05; **, p≤0.005).
Fig. 4. Concentration-dependence of PMCA inhibition by Aβ1-42 after pretreatment
with calmodulin. 2.5 μg PMCA were reconstituted in PC and incubated without (○)
and with 14 nM (□), 50 nM (♢) and 200 nM (△) calmodulin for 10 min at 25 °C, in
the presence of 3.16 μM free Ca2+ in 25 μl total volume. The mixture was then incubat-
ed with increasing concentrations of 2 h-aged Aβ1-42 (1 μl) for 3 min followed by di-
lution to 1 ml with assay medium, giving the indicated Aβ ﬁnal concentrations. Ca2+-
ATPase activity was measured after addition of 1 mM ATP. 100% activities correspond
to 0.941±0.12, 1.29±0.07, 1.53±0.12, and 1.78±0.17 μmol min−1 mg−1, in the ab-
sence or presence of 0.35 nM, 1.25 nM and 5 nM calmodulin (in 1 ml ﬁnal volume), re-
spectively. Data represent mean±SD values from four experiments performed in
duplicate and with three different preparations. The insert shows effects of Aβ over a
larger concentration range.
Fig. 5. Effects of calmodulin and Aβ on Ca2+-ATPase activity of proteolyzed PMCA. (A) 2.5 μg
or 0.5 μg calpain (Calp) for the indicated times, in a volume of 25 μl, on ice. Proteolysis was
cubated without (○,●) and with (△,▲) 30 μM 2 h-aged Aβ1-42 for 10 min at 37 °C. Incubat
absence (open symbols) or presence of 200 nM calmodulin (ﬁlled symbols). Data are mean
preparations. (B) Electrophoretic analysis of intact PMCA (lane 1) and fragments generated
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the absence of calmodulin (Fig. 5A), reaching Vmax after 20 min diges-
tion; addition of calmodulin increased the activity of intact PMCA and
PMCA digested for less than 20 min, to the maximum rate. These re-
sults show that the calmodulin binding site of PMCA was being grad-
ually removed by both proteases. Inhibition of ATPase activity by Aβ
was also seen to decrease with increasing time of digestion, with min-
imal inhibition being seen after ca. 20 min digestion (Fig. 5A). The ex-
tent of proteolysis was followed by SDS-PAGE (Fig. 5B), showing
degradation of the 140 kDa-native protein to a main 124 kDa frag-
ment after chymotrypsin and calpain treatments, which corresponds
to PMCA products lacking their calmodulin-binding domain, as a con-
sequence of 20 min incubation with proteases [22].
We have previously shown that hPMCA4b overexpressed in COS
cells can be speciﬁcally inhibited by Aβ [1]. In order to analyze the pu-
tative involvement of the C-terminal calmodulin-binding domain of
PMCA in Aβ binding, we used the hPMCA4b-L1086* mutant lacking
the C-terminal calmodulin-binding domain. The mutant was pre-
pared as described in the Methods and its kinetics properties with re-
spect to calmodulin and Aβ were compared to those of the wild type
(Fig. 6). The basal activity of wild-type PMCA4b was inhibited by Aβ,
and also was further activated by addition of calmodulin to the assay
medium (see white bars). It could also be completely activated when
it was preincubated with calmodulin or after removing its autoinhibi-
tory calmoduling-binding domain with calpain. The activated formsof PMCA were digested, as described in the Methods, with 0.025 μg chymotrypsin (CT)
stopped by addition of 2 mM PMSF and immediately afterwards, the samples were in-
es were added to assay medium (1 ml) and Ca2+-ATPase activity was measured in the
±SD values from three experiments performed in duplicate and with three different
by 20 min digestion with chymotrypsin (lane 2) and calpain (lane 3).
Fig. 6. Effects of preincubation with calmodulin and Aβ peptide on Ca2+-ATPase activity of full-length PMCA4b isoform and a truncated isoform lacking the calmodulin binding
domain. (A) Intact membrane vesicles (10 μg) from COS-7 cells overexpressing full-length hPMCA4b or the truncated mutant hPMCA4b-L1086* were incubated as indicated with-
out or with 400 nM calmodulin (preCaM) plus 3.16 free Ca2+ for 10 min at 25 °C in a volume of 25 μl, and then 30 μM aged Aβ1-42 (1 μl) was added and further incubated for 3 min
at 37 °C. Membrane vesicles (10 μg) were also digested with 2 μg of calpain in the presence of 3.16 free Ca2+ during 20 min on ice (striped bars) and afterwards incubated in the
absence or presence of Aβ1-42 as above. Incubates were added to assay medium (1 ml) and PMCA activity was measured as described in the Methods section also in the absence of
calmodulin or after addition of calmodulin up to 400 nM (white bars). Data represent mean±SD values from four experiments performed in duplicate and with three different
preparations (*, p≤0.005). (B) Schematic representation of the membrane topography of the full-length and truncated PMCA4b.
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basal activity than the wild-type enzyme, due to the loss of its autoin-
hibitory calmoduling-binding domain and could not be activated by
addition of calmodulin or be inhibited by Aβ. Further, incubation of
the mutant with calmodulin did not increase its activity, although cal-
modulin did increase the activity of the wild-type PMCA. These re-
sults strongly support those revealed by proteolysis experiments
and suggest that Aβ may bind to a site close to or at the calmodulin
binding site which is lacking in both digested PMCA and truncated
mutant.
An alternative hypothesis to explain the protective effect of cal-
modulin on PMCA inhibition by Aβ, is that calmodulin could also
bind to Aβ, reducing or even blocking the binding of Aβ to PMCA.
To test for a possible interaction between Aβ and calmodulin we
performed binding studies by Dot-blot overlay assays, using Aβ1-42
or the scrambled peptide and biotinylated calmodulin (Fig. 7).
Peroxidase-conjugated ExtrAvidin staining showed that calmodulin
did indeed interact with Aβ1-42. PMCA-calmodulin binding was
used as a positive control. An increase in dot intensity was seen
when Aβ and PMCA were mixed before being spotted onto the mem-
brane. This increase was due to calmodulin binding to both Aβ and
PMCA. Additional test were carry out by exploring the sensitivity ofFig. 7. Dot-blot overlay assay showing Aβ-calmodulin interaction. Two μg of 2 h-aged
Aβ1-42, and 0.2 μg of puriﬁed PMCA (as positive control) were spotted on nitrocellu-
lose membranes, separately and after mixing for 10 min. The membrane was incubated
with of biotinylated calmodulin, and treated as indicated in the Methods. Aβ42-1 was
spotted as a negative control. Dot intensities were represented as mean±SD of four
different experiments (*, p≤0.005).intrinsic ﬂuorescence in Aβ, calmodulin and PMCA to conformational
changes induced by Aβ binding. Emission ﬂuorescence spectra upon
exciting at 280 nm (which excites only Tyr residues) of each protein
and peptide were recorded independently and after pre-mixing the
peptide with PMCA or/and calmodulin (Supplementary Fig. S1). It
was found that when the Aβ peptide was preincubated with PMCA
or calmodulin the maximum of ﬂuorescence reached was lower
than the combined ﬂuorescence (calculated as the sum of ﬂuores-
cence peak values of each molecule). This indicated that Tyr residues
on Aβ and calmodulin were perturbed by the close interaction when
they were incubated together or/and with PMCA.4. Discussion
The Aβ peptide, a major component of senile plaques in patients
with AD, is believed to facilitate the progressive neurodegeneration
of this disease. Early studies have shown that Aβ1-42 is more insolu-
ble than the more abundant Aβ1-40, and that it is the most abundant
Aβ species found in senile plaques [23]. The shorter Aβ25-35 peptide
is not found in vivo, but it represents the main toxic part of the full
length Aβ peptides [24]. In this work, we show that synaptosomal
PMCA is inhibited by neurotoxic Aβ peptides in a length and
aggregation-dependence manner. The longest Aβ1-42 peptide pro-
duced the highest inhibition on PMCA activity, increasing this effect
with peptide aggregation (Fig. 1). This effect is related to the capacity
of this peptide to form more toxic ﬁbrils and faster than Aβ1-40 [25].
Besides, we found that binding of Aβ1-42 to PMCA is not proportional
to inhibition of PMCA activity. The maximum inhibitory effect was
obtained after reaching a certain oligomerization stage (as the one
formed at 2 h ageing) and not higher inhibition was found with fur-
ther aggregation stages. Thus, binding of 2 h- or 72 h-aged Aβ1-42
to PMCA may produce a similar conformational change that hinder
Ca2+ binding sites and then reduces PMCA activity. This fact could
be supported by recent Aβ-structural studies showing that residues
1–10 are unstructured in oligomers and ﬁbrils while the other
amino acids adopt a β-turn-β folding [26,27]. Thus, unstructured N-
terminal sites of Aβ could be involved in PMCA inhibition, becoming
inhibition not proportional to binding. Impairment of PMCA activity
by Aβ peptides appears to be important in amyloid toxicity, because
it might result in cytoplasmic Ca2+ dysregulation and explain the
different Ca2+-dependencies of PMCA activity observed in normal
967M. Berrocal et al. / Biochimica et Biophysica Acta 1822 (2012) 961–969and AD brains [1]. Here we show that effects of Aβ on PMCA are mod-
ulated by calmodulin and suggest a mechanism for the observed ef-
fects that is summarized in Scheme I.
PMCA contains a calmodulin-binding domain in its C-terminal tail
that, in an enriched neutral lipidic environment, acts as an endoge-
nous inhibitor [28] by establishing intramolecular contacts with two
cytosolic loops of the pump, which most probably prevent the access
of substrates to the active site [8]. Ca2+-calmodulin activates the
pump by removing the C-terminal tail from its intramolecular binding
sites [3], as shown in Scheme IA. Interestingly, the inhibitory effect of
Aβ on PMCA shown in this work does not impede further calmodulin
binding to the pump and its activation (Fig. 2). This suggests that Aβ
binding to PMCA occurs in a protein region that interferes with its
catalytic domain and slows the reaction cycle, thus inhibiting PMCA
activity, but without altering calmodulin binding and subsequent ac-
tivation (Scheme IB). This region may be located at the C-terminal tail
of PMCA, in or close to its calmodulin-binding domain. This is sug-
gested by the results obtained by limited proteolysis (Fig. 5). It is
well established that controlled proteolysis of the pump produces
PMCA fragments lacking the autoinhibitory calmodulin binding do-
main and which are therefore fully active and cannot be further stim-
ulated by calmodulin [12,20,21,29–31]. In agreement, the PMCA
fragments obtained here by limited proteolysis with chymotrypsin
and calpain showed higher activity than the native protein (Fig. 5).
This increase in activity was linked to a decrease in both its activation
by calmodulin and its inhibition by Aβ. After 20 min treatment with
either protease, the PMCA protein lost completely its calmodulin-
binding domain and was insensitive to the effects of calmodulin and
Aβ. Similar results were obtained with the PMCA4b-L1086* truncatedScheme I. Calmodulin and putative Aβ binding to PMCA based in activity assays. (A) shows
the tail with the catalytic core of PMCA and the formation of an active conformation. (B) sho
addition of calmodulin to the assay results in calmodulin binding to PMCA and activation, as
sites for calmodulin and Aβ. (D) PMCA preincubated with low concentrations of calmodulin
tivity. (E) represents PMCA preincubated with high concentrations of calmodulin and Aβ. It
binding of Aβ to free calmodulin, thus preventing the inhibitory effect of the peptide on PMC
peptide binds to calmodulin and free peptide also binds to PMCA, resulting in inhibition ofmutant (Fig. 6). Thus, truncation of the protein by proteolysis or by
site-directed mutagenesis prevents the inhibitory effect of Aβ (and
activation by calmodulin) on PMCA activity (Scheme IC).
Interestingly, pretreatment of PMCA with low concentrations of
calmodulin reduces the inhibitory effect of Aβ and blocks it totally
at high concentrations of calmodulin (Figs. 3A and 4). This suggests
that high afﬁnity binding of calmodulin to PMCA produces a confor-
mational change in PMCA, masking its binding site(s) for Aβ. The
protective effect of calmodulin is concentration-dependent because
calmodulin could not protect PMCA from its inhibition by high con-
centrations of Aβ (Fig. 4). These results suggest that the peptide
could also bind to calmodulin. In fact, Dot-blot overlay assays using
biotinylated calmodulin (Fig. 7) and measurements of intrinsic ﬂuo-
rescence (Fig. S1) point out a calmodulin-Aβ interaction. Then, it is
possible that the successive preincubation of PMCA with calmodulin
and Aβ resulted in the peptide binding to PMCA and/or calmodulin,
depending on the Aβ/calmodulin molar ratio (Scheme ID-F). Thus,
binding of Aβ to calmodulin would result in lowering the concentra-
tion of free Aβ available to bind to PMCA. However, high concentra-
tion of peptide binds to both calmodulin and PMCA, thus preventing
further binding of calmodulin to PMCA. Interestingly, it has been
reported that PMCA can be activated not only by full length Ca2+/
calmodulin but also by the C-terminal lobe of calmodulin alone
[32–34], leaving the N-terminal lobe of calmodulin free for other in-
teractions. Thus Aβ could also bind to its N-terminus inducing a
conformational change in calmodulin, thus preventing calmodulin bind-
ing to PMCA. Analysis of the Aβ1-42 sequence reveals a 1-8-14 motif
(DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA) character-
istic of calmodulin targets [32]. In fact, it has been proposed abinding of calmodulin to the C-terminal tail of PMCA leading to reduced interaction of
ws binding of Aβ to the C-terminal tail of PMCA leading to loss of activity. Subsequent
resulted in Fig. 2. (C) shows the active fragment of truncated PMCA that loss the binding
and with Aβ. It shows binding of calmodulin and Aβ to PMCA with partial loss of ac-
shows binding of calmodulin to PMCA leading to the active conformation of PMCA and
A activity. (F) PMCA preincubated with calmodulin and high concentrations of Aβ. The
PMCA activity.
968 M. Berrocal et al. / Biochimica et Biophysica Acta 1822 (2012) 961–969calmodulin connection with Alzheimer's disease (AD), based on the
presence of calmodulin binding domains in several AD-related pro-
teins, opening new ways to explore on this devastating disease
[35].
Although identiﬁcation of PMCA speciﬁc residues involved in Aβ
binding is complicated by the absence of reliable tertiary structural
characterization of the protein, it cannot be discarded that the inhib-
itory effects of Aβ follow from protein oxidation. First, Aβ itself has a
free radical-generating capacity [36] and Aβ induces peroxide accu-
mulation in cultured cells and antioxidants can protect against Aβ-
induced toxicity [37,38]. Second, PMCA has been found to be highly
susceptible to oxidative stress and its exposure to oxidants leads to
structural changes that result in loss of activity [39]. Third, it has
been reported that calmodulin binding to PMCA produces a confor-
mational change that might bury some residues susceptible to oxida-
tion [40] since the susceptibility of PMCA to the oxidant H2O2 is
reduced by prior exposure to calmodulin [41]. Moreover, results
from our lab show that antioxidants such as vitamin A or C complete-
ly protect PMCA activity from Aβ inhibition (unpublished results).
Further studies are required to fully characterize the mechanism of
inhibition of PMCA by Aβ.
Several studies have shown that a feature of aged brain is a reduc-
tion in calmodulin levels and/or calmodulin oxidation [42,43] as well
as oxidative damage to PMCA [40,44]. Reduced concentrations of cal-
modulin has also been shown in an age-related neurodegenerative
disorders such as AD [16]. This would result in a reduction or even a
lack of protective effect of calmodulin on PMCA inhibition by the neu-
rotoxic Aβ.
The ﬁnding that protective effect of calmodulin on PMCA inhibi-
tion by Aβ is dependent of peptide concentration involves a physio-
logical relevance in AD, since Aβ distribution is not homogeneous in
AD-affected brain; Aβ is highly concentrated in senile plaques that
appear to be local focus of neurotoxicity [45]. We propose calmodulin
as a new target in the study of AD, where it can play a protective role
at early stages of the disease. At advanced stages of AD, Aβ goes on to
form larger aggregates in plaques; then, high concentration of Aβ
would suppress the physiological protection by calmodulin on Aβ-
mediated PMCA inhibition, resulting in a decreased clearance of intra-
cellular Ca2+. Our work goes a step further, pointing out, by in vitro
assays, the protective use of exogenous calmodulin to target the neu-
rotoxic Aβ peptide, e.g. blocking the Aβ inhibitory effect on PMCA or
catching free Aβ and then reducing its neurotoxic effect. This would
result in restore the Ca2+ levels after Ca2+ dysfunction induced by
Aβ in neurodegenerative disorders. This study could establish a
basis to perform further in vivo studies with exogenous calmodulin
in animal models of AD.
Supplementary materials related to this article can be found on-
line at doi:10.1016/j.bbadis.2012.02.013.Acknowledgements
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